Esperion Therapeutics (United States)
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Esperion Therapeutics (United States), United States, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
43%
Total
Publications
175
Total Open
Publications
75
Total
Citations
12K
Open Access
Percentage
43%
Total
Publications
175
Total Open
Publications
75
Total
Citations
12K
Breakdown
Publisher Open
13%
Both
24%
Other Platform Open
6%
Closed
57%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 38%
25
Hybrid 31%
20
No Guarantees 31%
20
Other Platform Open
Domain 68%
36
Institution 26%
14
Other Internet 11%
6
Preprint 6%
3
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 36 |
DOI | Other Internet | 5 |
Royal Netherlands Academy of Arts and Sciences | Institution | 4 |
Washington University in St. Louis | Institution | 2 |
University of Milan | Institution | 2 |
medRxiv | Preprint | 2 |
Europe PMC | Domain | 2 |
Unknown Repository | Other Internet | 1 |
University of Michigan–Ann Arbor | Institution | 1 |
SLUB Dresden | Institution | 1 |